Cite

HARVARD Citation

    D'Haens, G. et al. (2022). Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 399 (10340), pp. 2015-2030. [Online]. 
  
Back to record